Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 June 2019Website:
http://bridgebio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:09:37 GMTDividend
Analysts recommendations
Institutional Ownership
BBIO Latest News
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.
- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA's requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s)
BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.
BridgeBio's stock is underperforming this year despite the progress the company made in recent quarters. HELIOS-B trial of Alnylam's Amvuttra (vutrisiran) was keeping investors away from BridgeBio, but the data presentation this week should lift this overhang on the stock. Investor focus should turn to the potential FDA approval and launch of acoramidis for the treatment of ATTR CM, followed by three late-stage clinical readouts in 2025.
PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 – September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 - 30, 2024.
PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the management team will participate in the following upcoming investor conferences:
The FDA accepted BridgeBio Pharma, Inc.'s NDA regulatory submission of Acoramidis for the treatment of patients with ATTR-CM and set a PDUFA date of November 29th of 2024. Partnership established with Bayer to commercialize Acoramidis for the treatment of patients with ATTR-CM in European territories; Regulatory approval for Europe expected in 2025. The transthyretin amyloidosis treatment market size is expected to reach $11.2 billion by 2032.
What type of business is BridgeBio Pharma?
BridgeBio Pharma, Inc. is a pharmaceutical company engaged in research and development of various drugs for genetic diseases. The company was founded in 2015, with its headquarters located in Palo Alto, California. BridgeBio Pharma's portfolio includes about 20 development programs for various products at different stages of development. The company's main candidates are: BBP-265, an oral low-molecular-weight transthyretin (TTR) intended for the treatment of transthyretin amyloidosis. Infigratinib, an oral selective FGFR1-3 tyrosine kinase inhibitor for the treatment of FGFR-driven cancer and achondroplasia. BBP-631, a preclinical gene transfer candidate product for the treatment of congenital adrenal hyperplasia (CAH) caused by 21OHD. BBP-454, a preclinical research program focused on new approaches to inhibiting KRAS for cancer treatment.
What sector is BridgeBio Pharma in?
BridgeBio Pharma is in the Healthcare sector
What industry is BridgeBio Pharma in?
BridgeBio Pharma is in the Biotechnology industry
What country is BridgeBio Pharma from?
BridgeBio Pharma is headquartered in United States
When did BridgeBio Pharma go public?
BridgeBio Pharma initial public offering (IPO) was on 27 June 2019
What is BridgeBio Pharma website?
https://bridgebio.com
Is BridgeBio Pharma in the S&P 500?
No, BridgeBio Pharma is not included in the S&P 500 index
Is BridgeBio Pharma in the NASDAQ 100?
No, BridgeBio Pharma is not included in the NASDAQ 100 index
Is BridgeBio Pharma in the Dow Jones?
No, BridgeBio Pharma is not included in the Dow Jones index
When was BridgeBio Pharma the previous earnings report?
No data
When does BridgeBio Pharma earnings report?
Next earnings report date is not announced yet